Stem Cell Banking: Your Own Cells

Stem cells are often presented as either breakthrough or hype. Neither framing is useful. The reality is more measured. The biology is real. The mechanisms are increasingly understood. The clinical results are mixed but often positive in specific settings. The field is moving, but it is not finished.

At Regeneris, the approach is straightforward. The goal is not immediate treatment but preparation. A small fat harvest is performed, usually from the flank or lower back where there is accessible adipose tissue. About 20 cubic centimeters are removed using a cannula. The procedure takes one to two hours under local anesthesia. “It’s essentially a painless procedure with just some local numbing medicine,” Dr. Ryan Welter says.

That fat contains mesenchymal stem cells. These cells do not function as replacement parts. They do not reliably turn into cartilage or tendon in a direct way. Their role is regulatory. They release signaling molecules, reduce inflammation, and recruit other cells to areas that need repair. “What cell therapy does is initiate cascades at areas of injury,” he explains. These cells can differentiate into various cell types to treat diseases such as lymphoma, leukemia, and immune disorders. Stored cells can be used to treat over 80 conditions, including leukemia, lymphoma, and various genetic or blood diseases. Cellular therapy using these cells is being explored for a wide range of clinical applications.

Once harvested, the tissue is packaged and shipped overnight to a processing laboratory. In this model, Regeneris works with companies such as American Cell Technology for adipose-derived cells and Acorn Biolabs for follicular-derived products. The fat sample is received, processed, and expanded. The expansion phase takes about three weeks. During that time, a small starting population of cells is grown into a usable quantity. The genetic material of the cells is preserved during cryopreservation and expansion, ensuring the cells remain genetically matched to the donor.

After expansion, the cells are cryopreserved and stored long term. This becomes a personal biological reserve. “They’ll remain at the same age that you are,” Dr. Welter says. That point is central. Stem cells decline in function with age. They divide more slowly, show more senescence, and are less effective in repair. Banking earlier preserves a higher-functioning version of one’s own cells.

The storage model is not static. A portion of the cells is kept as a “seed” batch. When needed, that batch can be expanded again. This allows for repeated use over time rather than a single fixed supply. The turnaround for a fresh expansion is typically about three weeks from the time of request.

There is also a faster-access model. Some programs allow pre-expansion and storage of ready-to-use doses. In that case, cells can be retrieved and delivered within days rather than weeks. This is sometimes described as a form of biological insurance, where availability matters as much as capability.

A parallel pathway exists using hair follicles. A small number of follicles can be harvested and sent to a lab such as Acorn. These cells are also expanded and stored, but they are often used to generate a secretome, a collection of exosomes and growth factors derived from the cells. These products can be used more immediately. Patients may receive a series of vials for topical or in-office use. “They will give you a set of exosomes from your own stem cells,” he says. Some patients use part of the supply in clinic and take the remainder home for ongoing application.

The clinical uses follow the biology. In joint disease, especially osteoarthritis, studies show improvements in pain and function over one to two years in many patients. The effect is not uniform. It depends on disease stage, cell preparation, and patient factors. The mechanism appears to be anti-inflammatory and signaling-based rather than structural regeneration. Some imaging suggests slowed progression in earlier disease, but advanced degeneration is not reversed. Cellular therapy and MSC therapy are also being studied in clinical trials for their potential to treat diseases beyond joints, including autoimmune and neurodegenerative conditions.

In aesthetics, the applications are more straightforward. Adding stem cells to fat grafts can improve graft survival. Skin treatments that combine microneedling with cell-derived factors may improve texture and elasticity. Hair restoration protocols using follicular-derived exosomes are being studied and show early promise.

Beyond these uses, claims become more speculative. Systemic “longevity” applications are discussed but not well supported by human trials. The science suggests potential, but the evidence is not yet strong enough to define clear protocols or outcomes. Clinical trials are exploring stem cells for treating additional conditions such as autism, cerebral palsy, Type 1 diabetes, and neurodegenerative diseases like Alzheimer’s.

The regulatory environment reflects that uncertainty. Expanded stem cell products are regulated more strictly and often fall under drug classification. Their therapeutic use may require clinical trial pathways or specific approvals. Clinical studies investigating the efficacy of mesenchymal stem cells are ongoing worldwide, particularly for autoimmune diseases, graft versus host disease, Crohn’s disease, multiple sclerosis, systemic lupus erythematosus, and systemic sclerosis. Many of the early clinical successes using intravenous transplantation came in systemic diseases such as graft versus host disease and sepsis. Researchers are also exploring the potential of mesenchymal stem cell therapy to protect nerves from damage and to encourage the repair of existing damage, including studies involving MSC injection into the fluid surrounding the spinal cord in people with progressive MS. An early pilot study involved ten people with progressive MS, and researchers tested the safety and effectiveness of MSC injection into the fluid surrounding the spinal cord. The first regulatory approvals for MSCs were granted conditional approval in 2012 in Canada and New Zealand for treating Graft vs. Host Disease (GvHD), and MSC therapy was approved by the FDA in the United States in 2024 for GvHD.

Cost is part of the equation. The adipose-derived stem cell banking process is typically around $10,000. This includes the procedure, processing, initial expansion, and storage setup. There are often ongoing storage fees and costs associated with future retrieval and expansion. The follicular-based approach is less expensive, often around $5,000, and includes a set of exosome products for near-term use.

Insurance does not cover these services. This is an out-of-pocket decision. The benefit is not immediate. There is no guarantee that the cells will be used, or that future treatments will outperform other options that may exist at that time.

At the same time, the risk profile is low. The cells are autologous. They come from the patient and are returned to the same patient. The harvesting procedure is minor. There is no evidence that these approaches worsen underlying conditions. Compared to surgical interventions, the risk is minimal.

The argument for doing this now rather than later rests on one point. Cell quality declines with age. Banking earlier captures a more functional version of your biology. Waiting until disease develops means working with older, less effective cells.

This is where the decision becomes personal. It is not about urgency. It is about how one thinks about the future.

For many, this becomes a form of practical preparation. “Think about having a lifetime of your own stem cells at your fingertips,” Dr. Welter says. The procedure fits into a single visit and requires little disruption to daily life. It can be coordinated with other treatments.

In the end, stem cell banking is less about immediate results and more about readiness. It is a way of setting something aside for a future moment when the body may need support. The price point is not trivial, at roughly $10,000 for preservation of mesenchymal cells, and it sits outside the current insurance framework. It invites comparison to life insurance or other long-term planning tools. One does not expect to use it often, but when the need arises, having it available may matter.

The science supports parts of this logic. Younger cells function better. Signaling pathways can influence repair. Clinical studies show benefit in certain conditions. MSCs have shown promising results in preclinical studies, but more research is needed to fully understand their potential and to develop safe and effective therapies. At the same time, the field is still developing. Results vary. Regulations are evolving. Future therapies may improve on what is available now.

This is not a cure. It is not a guarantee. It is a forward-looking decision based on current science and expected progress. For some, that is enough. For others, it remains a step too early.

The middle ground is where it belongs. It is not snake oil. It is not settled medicine. It is a developing tool with a clear biological rationale, early clinical support, and a cost that forces a decision.